Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Net Cash Flow (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Net Cash Flow data on record, last reported at -$2.9 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 112.49% year-over-year to -$2.9 million; the TTM value through Dec 2025 reached -$10.8 million, down 132.18%, while the annual FY2025 figure was -$10.8 million, 132.18% down from the prior year.
  • Net Cash Flow reached -$2.9 million in Q4 2025 per TRDA's latest filing, down from $20.8 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $182.5 million in Q1 2023 and bottomed at -$202.5 million in Q1 2022.
  • Average Net Cash Flow over 4 years is -$12.3 million, with a median of -$1.0 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: soared 292.79% in 2023, then tumbled 4101.68% in 2025.
  • A 4-year view of Net Cash Flow shows it stood at -$8.2 million in 2022, then skyrocketed by 292.79% to $15.7 million in 2023, then soared by 47.34% to $23.2 million in 2024, then crashed by 112.49% to -$2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$2.9 million in Q4 2025, $20.8 million in Q3 2025, and $4.6 million in Q2 2025.